Alternative switching strategies based on regimens with a low genetic barrier: do clinicians have a choice nowadays?
- PMID: 30443683
- DOI: 10.1007/s10096-018-3429-x
Alternative switching strategies based on regimens with a low genetic barrier: do clinicians have a choice nowadays?
Abstract
Clinicians sometimes use switching strategies based on regimens such as RAL + ABC/3TC or RPV + ABC/3TC in order to resolve tolerability or safety issues associated with conventional recommended first-line strategies. Despite the low genetic barrier of these regimens, high safety and efficacy rates have been reported in retrospective studies.
Keywords: Abacavir/lamivudine; Efficacy; Raltegravir; Rilpivirine; Safety; Switching.